CompletedNCT02157077
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
PHASE3 · 84 planned enrolment
- Countries listed
- 1
- Registry update
- October 5, 2026
immortal.lifeTrial registrations containing the exact intervention label Aflibercept.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 84 planned enrolment
PHASE2 · PHASE3 · 960 planned enrolment
PHASE3 · 534 planned enrolment